Please login to the form below

Not currently logged in
Email:
Password:

Biogen appoints executive VP, corporate development

Daniel Karp will also become a member of the executive committee

Daniel KarpBiogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June.

Karp’s new role will see him lead the newly created corporate development function, which will include corporate and business development and corporate strategy.

He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience.

“Daniel's solid experience from Pfizer combined with his scientific and business education will serve him well in this exciting position as we aim to further build our pipeline and portfolio to tackle unmet needs in neurological diseases.”

Daniel joins Biogen from Pfizer where he most recently was Vice President, Worldwide Business Development and head of business development for R&D.  In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer's research portfolio.

He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.  "I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”

11th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics